Focus Biobank Inflammatory Bowel Disease University Hospitals Leuven KU Leuven Isabelle Cleynen, PhD
Inflammatory Bowel Disease Crohn s disease (CD) Entire GI tract Transmural Fistulas and/or strictures Abdominal cramps Weight loss Bloody diarrhea 2-3/1,000 prevalance Ulcerative colitis (UC) Colon only Continuous Mucosal Blood loss Diarrhea 4/07/2013 2
The spectrum of IBD... 4/07/2013 3
IBD biobank Since 1997 High quality collection of well-annotated samples in a prospective long-term project linked to the clinical patient cohort Overall objectives: to strengthen research into mechanisms and genetics of the disease to enable development of better biomarkersto guide therapy and management to support development of better diagnostics and treatment IRB approved (B322201213950/S53684) 4/07/2013 4
IBD biobank DNA, serum, biopsies, faecal samples after IC Serial serum samples before and after start biologic therapies (anti-tnf, vedolizumab...) IBD population Control population Unique samples CD UC IC PSC Unaffected relatives Healthy spouses Healthy volunteers Non-IBD controls 2250 1150 86 178 4999 517 609 115 TOTAL 3544 4999 1241 Serial samples (±7 per patient) >12.000 samples Infliximab Adalimumab Vedolizumab 1198 672 132 4/07/2013 5
General considerations when creating a biobank Privacy of patients Anonymous and unique identification number Informed consent Computerized All persons working with the database should know program used ACCESS Back-up through hospital server Safety Passwords: limited access for different people 4/07/2013 6
IBD biobank 4/07/2013 7
Storage via 2D barcode system 4/07/2013 8
IBD biobank: Achievements and valorisation IBD Genetics International IBD Genetics Consortium (IIBDGC) full partner since its start in 1997 led to a number of important publications (Nature, Nat Genetics...) which have had a major impact on the field of complex genetics Belgian IBD Genetics Consortium KU Leuven, UGent, ULG Liege and Erasme Brussels feeding samples into the genetic biobank for use in international projects 4/07/2013 9
IBD biobank: Achievements and valorisation Biomarker development and validation of diagnostic/therapeutic assays: studies on new and existing biomarkers studies on the validity of the assays systematic banking of serum samples before and during treatment with biological therapies to optimize therapy via trough level measurement (collaboration with Ann Gils from Pharmabs) 4/07/2013 10
IBD biobank: Achievements and valorisation Expression studies: paired biopsies from patients before and after start of biological therapies Micro-array expression studies to identify predictive signatures for response to therapy 4/07/2013 11
IBD biobank Unmet needs
IBD biobank: Unmet needs Funding IBD biobank has been developed on a patchwork of funding (FWO, Chairs, GOA, ), continuously threatening the stability of the project No integrative system for storage/consultation of samples, phenotypes results from genotypes/serology Integrative systems are being explored SLims, etrinity, CA Tissue No direct link between the biobank and the KWS would allow constant update on changing nature of the disease in given patient 4/07/2013 13
IBD biobank Unmet needs -example Anti-TNF successfully used in many IBD patients, but 40% lose response 15-20% primary non-responders Does this genetic mutation influence response to anti-tnf therapy in IBD patients? 4/07/2013 14
IBD biobank Unmet needs -example 4/07/2013 15
IBD biobank Unmet needs -example 4/07/2013 16
THANK YOU Questions?